source
- mRNA cancer vaccines’ biggest barriers to marketManufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
- FDA grants three-month review extension for Exelixis' metastatic colorectal cancer candidateExelixis, a California drug developer, has provided the FDA with additional safety and efficacy data for its experimental therapy aimed at treating metastatic colorectal cancer. The agency respond…